From the March 24, 2020, edition of Fox News' Fox & Friends

BRIAN KILMEADE (CO-HOST): Alright, so as you know, Dr. Siegel, we are going to try today in New York hydroxychloroquine combined with a Z-pak and to see where this antimalarial drug will bring us in terms of lessening the symptoms or the recovery time or save lives. One of the men whose life was saved because of this said goodbye to his family already and then took this and is now -- was on our show 45 minutes ago. Listen to him.

…

KILMEADE: Dr. Siegel, is it the answer for a lot of people?

DR. MARC SIEGEL (FOX NEWS MEDICAL CONTRIBUTOR): It may very well be. That was a very, very stirring interview, Brian. Let me tell you, I'm looking around the world and there's two malaria drugs, hydroxychloroquine and chloroquine, and in the test tube, the hydroxychloroquine looked much more powerful against this virus. It definitely has properties against the virus. They've used it in South Korea, they used it in China. There was a small study out of France on this that looked very promising. Medical centers around the country are using it, University of Washington, University of Minnesota is studying it. Now as you just said, New York is starting to study it. The WHO is a multi-center trial around the world. I think that -- My view on this, based on talking to many scientists, is it works especially well pretty early in the game. So, in other words, if you are a severe case, or you have a lot of high risks, this may be for you. And I came on last night on Tucker right after Dr. Hahn from the FDA and I was so happy to hear what he said. He said your doctor should sit down your patient, or as you just said, telemedicine with your patient, and determine on a case-by-case basis whether this might be something to use. That's how decisions need to be made right now. What's the clinical benefit? It's approved off-label for malaria, but maybe doctors can use it for this, if it's the right case, as we study it. I'm all for this.

KILMEADE: It might not be the magic formula but at least it's worth a try.